The OJC Episode 61: New Dimensions in the Hallmarks of Cancer

Join Eva Segelov, Craig Underhill and Hans Prenen as they chat through the latest papers.

In today’s episode Eva talks us through the third iteration of the Hanahan’s ‘Hallmarks of Cancer’. Hans gets stuck into a phase 2 trial in pleural mesothelioma and a Nature paper on HER-2 positive gastric cancer. Craig then gives us a fascinating walk through FDA approvals in 2021.

We’ve quick bites, ‘The Paper That Changed My practice’ segment and the amazing paper of the week… don’t miss another great episode of The Oncology Journal Club podcast!

This Week’s Papers:

1. Hanahan D. Hallmarks of Cancer: New Dimensions. Cancer Discov. 2022 Jan;12(1):31-46. doi: 10.1158/2159-8290.CD-21-1059. PMID: 35022204. Access online here.
2. Forde PM, et al. Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial. Nat Med. 2021 Nov;27(11):1910-1920. doi: 10.1038/s41591-021-01541-0. Epub 2021 Nov 8. PMID: 34750557; PMCID: PMC8604731. Access online here.
3. Janjigian YY, et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature. 2021 Dec;600(7890):727-730. doi: 10.1038/s41586-021-04161-3. Epub 2021 Dec 15. PMID: 34912120. Access online here.
4. 2021 FDA APPROVALS OF DRUGS FOR CANCER TREATMENT. Monday, December 27, 2021. The ASCO Post. Access online here.

This Week’s Quick Bites:

1. Milestones in cancer. Milestones | 10 December 2020. Nature. Access online here.
2. Lythgoe MP, et al. The iceberg plot, improving the visualisation of therapy response in oncology in the era of sequence-directed therapy. Eur J Cancer. 2021 Dec;159:56-59. doi: 10.1016/j.ejca.2021.09.034. Epub 2021 Nov 1. PMID: 34736043. Access online here.
3. Kendrick, M., et al. A qualitative study of hospital clinical staff perceptions of their interactions with healthcare middle managers. Journal of Health Organization and Management. 20 December 2021. Access online here.
4. Postow MA, et al. Adaptive Dosing of Nivolumab + Ipilimumab Immunotherapy Based Upon Early, Interim Radiographic Assessment in Advanced Melanoma (The ADAPT-IT Study). J Clin Oncol. 2021 Dec 20:JCO2101570. doi: 10.1200/JCO.21.01570. Epub ahead of print. PMID: 34928709. Access online here.
5. Redston M, et al. Abnormal TP53 Predicts Risk of Progression in Patients With Barrett’s Esophagus Regardless of a Diagnosis of Dysplasia. Gastroenterology. 2021 Oct 29:S0016-5085(21)03710-0. doi: 10.1053/j.gastro.2021.10.038. Epub ahead of print. PMID: 34757142. Access online here.
6. Nakamura Yet al. Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial. Nat Med. 2021 Nov;27(11):1899-1903. doi: 10.1038/s41591-021-01553-w. Epub 2021 Nov 11. PMID: 34764486; PMCID: PMC8604726. Access online here.
7. Reck M, et al. First-Line Immunotherapy for Non-Small-Cell Lung Cancer. J Clin Oncol. 2022 Jan 5:JCO2101497. doi: 10.1200/JCO.21.01497. Epub ahead of print. PMID: 34985920. Access online here.
8. Hopkins AM, et al. Efficacy of first-line atezolizumab combination therapy in patients with non-small cell lung cancer receiving proton pump inhibitors: post hoc analysis of IMpower150. Br J Cancer. 2022 Jan;126(1):42-47. doi: 10.1038/s41416-021-01606-4. Epub 2021 Oct 28. PMID: 34711947. Access online here.

Amazing Article of The Week:

Wallis CJ, Det al. Association of Surgeon-Patient Sex Concordance With Postoperative Outcomes. JAMA Surg. 2021 Dec 8:e216339. doi: 10.1001/jamasurg.2021.6339. Epub ahead of print. PMID: 34878511; PMCID: PMC8655669. Access online here.

The Paper That Changed My Practice:

Temel JS, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010 Aug 19;363(8):733-42. doi: 10.1056/NEJMoa1000678. PMID: 20818875. Access online here.

This Week’s Team:

Professor Eva Segelov

Eva Segelov

Professor Eva Segelov is a Medical Oncologist and is Director of Oncology at Monash University and Monash Health, Melbourne, Victoria, previously Senior Medical Oncologist at St Vincent’s Hospital, St Vincent’s Private Hospital and St Vincent’s Clinic and Associate Professor of Medicine, University of New South Wales.

Eva has an interest in academic clinical trials in GI and breast cancer and has been a member of the AGITG since 2003. She has clinical trials expertise, links with national and international trials groups, and extensive experience with adult medical education. You can find Eva on Twitter here: @profevasegelov

Professor Hans Prenen

Hans Prenen

Professor Hans Prenen is a medical oncologist and head of the phase 1 – early clinical trials unit at the Antwerp University Hospital in Belgium. He is a member of several scientific organisations, published many scientific oncology papers in prestigious journals and is regularly invited for lectures at national and international meetings.  His interests are clinical trials and translational research with a focus on digestive oncology. You can find Hans on Twitter here: @HPrenen

Associate Professor Craig Underhill

Craig Underhill

Associate Professor Craig Underhill completed his Bachelor of Medicine and Surgery in 1987 at Melbourne University. He completed medical oncology training in Melbourne and worked as the Senior Clinical Research Registrar at Guy’s Hospital, London.

In 1998 arrived in Albury-Wodonga and established a medical oncology practice and clinical trials unit which has developed expertise and infrastructure to ensure the initiation of high quality trials. The research Unit lead by Dr Underhill has twice been awarded NSW Premier’s Award for Innovation in Cancer Clinical Trials, the inaugural award in 2009 and then again in 2012.

Dr Underhill is the VCCC Regional Oncology Lead and advocates for the increased access to clinical trials for regional Victorians and leads the VCCC teletrials program. You can find Craig on Twitter here: @CraigUnderhill 

Dr Chandra Diwakarla

Chandra Diwakarla

Dr Chandra Diwakarla is a Medical Oncologist based at Fiona Stanley and Royal Perth hospitals having moved to WA from Canberra.

Chandra completed her fellowship training with extensive experience in both tertiary and rural environments across the ACT, NSW and WA. She is currently under taking her PhD studies investigating the role of novel therapies for the management of aggressive forms of breast cancer through the Australian National University.

Chandra has a particular interest in junior medical staff mentoring and teaching. She was the 2020-21 chair of YOGA and has been involved in treatment protocol development along with various quality assurance programs across the country.

You can find Chandra on Twitter here: @oncologyknitwit

Rachael Babin is Editor-in-Chief of The Oncology Newsletter, Publisher of Oncology News Host of The Oncology Podcast and Producer of The Oncology Journal Club. For regular oncology updates for healthcare professionals, please subscribe to The Oncology Newsletter.

Connect with us on Twitter @OncologyNewsAus